Authors:
QUILLENT C
OBERLIN E
BRAUN J
ROUSSET D
GONZALEZCANALI G
METAIS P
MONTAGNIER L
VIRELIZIER JL
ARENZANASEISDEDOS F
BERETTA A
Citation: C. Quillent et al., HIV-1-RESISTANCE PHENOTYPE CONFERRED BY COMBINATION OF 2 SEPARATE INHERITED MUTATIONS OF CCR5 GENE, Lancet, 351(9095), 1998, pp. 14-18
Authors:
DEGA H
ELIASZEWICZ M
GISSELBRECHT M
FLEURY J
PIALOUX G
JANSSEN B
DESAINTMARTIN L
GONZALEZCANALI G
DUPONT B
Citation: H. Dega et al., INFECTIONS ASSOCIATED WITH TOTALLY IMPLANTABLE VENOUS ACCESS DEVICES (TIVAD) IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS, Journal of acquired immune deficiency syndromes and human retrovirology, 13(2), 1996, pp. 146-154
Authors:
PIALOUX G
EXCLER JL
RIVIERE Y
GONZALEZCANALI G
FEUILLIE V
COULAUD P
GLUCKMAN JC
MATTHEWS TJ
MEIGNIER B
KIENY MP
GONNET P
DIAZ I
MERIC C
PAOLETTI E
TARTAGLIA J
SALOMON H
PLOTKIN S
Citation: G. Pialoux et al., A PRIME-BOOST APPROACH TO HIV PREVENTIVE VACCINE USING A RECOMBINANT CANARYPOX VIRUS EXPRESSING GLYCOPROTEIN-160 (MN) FOLLOWED BY A RECOMBINANT GLYCOPROTEIN-160 (MN LAI)/, AIDS research and human retroviruses, 11(3), 1995, pp. 373-381
Authors:
SALMONCERON D
EXCLER JL
SICARD D
BLANCHE P
FINKIELSTZJEN L
GLUCKMAN JC
AUTRAN B
MATTHEWS TJ
MEIGNIER B
KIENY MP
VALENTIN C
GONNET P
DIAZ I
SALOMON H
PIALOUX G
GONZALEZCANALI G
PLOTKIN S
Citation: D. Salmonceron et al., SAFETY AND IMMUNOGENICITY OF A RECOMBINANT HIV TYPE-1 GLYCOPROTEIN-160 BOOSTED BY A V3 SYNTHETIC PEPTIDE IN HIV-NEGATIVE VOLUNTEERS, AIDS research and human retroviruses, 11(12), 1995, pp. 1479-1486
Authors:
LORTHOLARY O
PIALOUX G
DUPONT B
TROTOT P
VAZEUX R
MIKOL J
THIEBAUT JB
GONZALEZCANALI G
Citation: O. Lortholary et al., PROLONGED SURVIVAL OF A PATIENT WITH AIDS AND PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, Clinical infectious diseases, 18(5), 1994, pp. 826-827